Condition

Primary CNS Tumors (2)

Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors (1)

Breast Cancer (1)

Cholangiocarcinoma (1)

Gastric Cancer (1)

Locally Advanced Solid Tumors (1)

Lymphoma (1)

Metastatic Solid Tumors (1)

Urothelial Cancer (1)

Overall Status

Active, not recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1/phase 2 (2)

Sponsor

Taiho Oncology, Inc. (1)

Turning Point Therapeutics, Inc. (1)

Collaborator

Intervention

futibatinib (1)

oral repotrectinib (tpx-0005) (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

primary cns tumors

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))

Recruiting

Locally Advanced Solid Tumors
+3 more

Oral repotrectinib (TPX-0005)

Los Angeles, California
+27 more

Aug 9, 2022

Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors Trial in

Active, not recruiting

Cholangiocarcinoma
+5 more

Futibatinib

Gilbert, Arizona
+57 more

Jan 5, 2022